

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gad, et al.
U.S. Serial No. : Not Yet Known (Continuation Application
of PCT/US99/22402, filed 24 September
1999)
Filed : Herewith
For : COPOLYMER 1 RELATED POLYPEPTIDES FOR
USE AS MOLECULAR WEIGHT MARKERS AND FOR
THERAPEUTIC USE

1185 Avenue Of The Americas
New York, New York 10036
March 23, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231
Box: Patent Application

Sir:

PRELIMINARY AMENDMENT TO THE ACCOMPANYING CONTINUATION
APPLICATION FILED UNDER 37 C.F.R. §1.53

Applicants request that the following amendment be made in the
above-identified application:

In the Specification:

On page 1, after the title, please delete the first sentence and
insert the following new sentence:

--This application is a continuation of PCT International
Application No. PCT/US99/22402, filed September 24, 1999,
designating the United States of America, which is claiming
the priority of U.S. Provisional Application No.
60/101,693, filed September 25, 1998, the contents of which
are hereby incorporated by reference into the present
application.--

Alexander Gad, et al.
U.S. Serial No. : Not Yet Known
(Continuation Application of
PCT/US99/22402, filed 24 September 1999)
Filed: Herewith
Page 2

In the Claims:

Please cancel claims 1-19, 21-33, 36-45, 47-48, 50-69, 92-93, and 104-122 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

REMARKS

This application is a continuation of PCT International Application No. PCT/US99/22402, filed 24 September 1999, designating the United States of America, which is claiming the priority of U.S. Provisional Application No. 60/101,693, filed September 25, 1998. Accordingly, the parent application, PCT International Application No. PCT/US99/22402, is pending today in the United States of America pursuant to 35 U.S.C. §363, and the subject continuation application is co-pending therewith in fulfillment of the provisions of 35 U.S.C. §120.

By this Preliminary Amendment, applicants have hereinabove amended the specification on page 1 to insert the continuation data. Applicants maintain that the amendments made hereinabove do not raise any issue of new matter. Accordingly, applicants respectfully request entry of the Amendment.

Claims 1-122 were pending in the subject application. By this Amendment applicants have canceled claims 1-19, 21-33, 36-45, 47-48, 50-69, 92-93, and 104-122 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application. Accordingly, upon entry of this Amendment, claims 20, 34-35, 46, 49, 70-91, and 94-103 will be pending and under examination.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Figure 1. The 1000 most abundant proteins in the *Salmonella* proteome. The proteins are ordered by molecular weight (MW) and pI. The x-axis represents the molecular weight in kDa, ranging from 0 to 100. The y-axis represents the pI, ranging from 3 to 11. The proteins are color-coded by function: red for metabolic, blue for structural, green for regulatory, and yellow for other functions. The plot shows a dense distribution of proteins across the entire range of MW and pI, with a higher density of proteins in the 10-50 kDa range.

John DeWitt

John P. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400